slides · global inventory
Problem Agitate Solution Problem Identify Pain
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 3,748
Current window 2,941-2,970
Pages 125
Rows per page 30
Beat
2,941-2,970 of 3,748
03
Uses a rhetorical question to frame the company's value proposition as a paradigm shift.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
Uses a process diagram to illustrate the iterative, inefficient nature of traditional drug discovery.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide uses a pipeline table format to show the progression of various drug candidates (SPY001-SPY230) across discovery, IND-enabling, and clinical stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
06
The slide uses a donut chart to compare 2021 and 2028 market sizes, highlighting growth.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
07
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
08
The chart uses a visual metaphor of a 'ceiling' (the 40% remission line) and an arrow to indicate the desired shift in therapeutic performance.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Golden Circle1 hit
07
Uses a geographic map and a nested circle diagram to illustrate the treatment gap.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
Kaplan-Meier survival curve showing probability of no relapse over 48 weeks.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · ProblemLoop · Before After1 hit
06
The slide uses a spiral/funnel-like diagram to illustrate the compounding nature of patient challenges.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
04
Uses a comparative structure to contrast Sepsis vs Septic Shock, followed by impact metrics.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide uses a process diagram to contrast current clinical workflows with the proposed solution, followed by a bar chart illustrating the exponential mortality risk over time.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
Includes a Kaplan-Meier survival curve, an anatomical illustration of tumor locations, and a comparative table of clinical outcomes.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a comparison framework to contrast existing treatments for other conditions with the lack of treatments for FSAD.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
09
This slide outlines regulatory requirements for clinical trial design, including placebo run-in periods, patient population definition, PRO instruments, and primary endpoints.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
10
Dare Bioscience | Investor Presentation Deck | 27 slidesDare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
Includes a visual comparison indicating FSAD is not equal to HSDD.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
Uses medical diagnostic criteria (DSM) to frame the business opportunity by analogy.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
13
The slide uses a bulleted list structure to categorize the patient experience into physical symptoms, motivations, emotional impact, and psychological concerns.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
04
Uses a visual metaphor of a fax machine to emphasize the inefficiency.Doximity | Investor Presentation Deck | 18 slides · Doximity
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
14
The slide uses a biological process diagram to illustrate the mechanism of immune activation.Enochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
16
MindMed | Investor Day Presentation Deck | 61 slidesMindMed | Investor Day Presentation Deck | 61 slides · MindMed
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
17
MindMed | Investor Day Presentation Deck | 61 slidesMindMed | Investor Day Presentation Deck | 61 slides · MindMed
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
18
The slide illustrates a standard psychiatric treatment escalation model.MindMed | Investor Day Presentation Deck | 61 slides · MindMed
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
19
The slide uses a comparison table to establish the 'problem' of current standard-of-care limitations.MindMed | Investor Day Presentation Deck | 61 slides · MindMed
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
01
Nano Dimension | Mergers and Acquisitions Presentation Deck | 12 slidesNano Dimension | Mergers and Acquisitions Presentation Deck | 12 slides · Nano Dimension
Activist deck Investment bank Beat · Problem1 hit
02
Nano Dimension | Mergers and Acquisitions Presentation Deck | 12 slidesNano Dimension | Mergers and Acquisitions Presentation Deck | 12 slides · Nano Dimension
Activist deck Investment bank Beat · Problem1 hit
03
Nano Dimension | Mergers and Acquisitions Presentation Deck | 12 slidesNano Dimension | Mergers and Acquisitions Presentation Deck | 12 slides · Nano Dimension
Activist deck Investment bank Beat · Problem1 hit
04
Includes a progress bar at the bottom indicating 'Intro' section.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
OKYO Pharma | Results Presentation Deck | 25 slidesOKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations Beat · Problem1 hit
07
The slide uses a table to frame the problem by contrasting existing market solutions with their clinical and commercial shortcomings.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations Beat · Problem1 hit